Sign in

Florian P Bayer

@flobayer.bsky.social
111 followers 121 following 48 posts

PhD student in PTM proteomics @kusterlab

PostsRepliesMedia
Reposted by Florian P Bayer
Lindsay K Pino @lindsaykpino.com · 28/05/2026
Chemoproteomics is back at #ASMS2026 with a bang! After the oral session mysteriously vanished last year, now we're not only back on the schedule but kicking off the conference with Ben Cravatt?! 1/n
2123
Reposted by Florian P Bayer
PastelBio @pastelbio.bsky.social · 20/12/2025
Proteoforms as the true units of physiological function link.springer.com/ar... --- #proteomics #prot-paper
011
Florian P Bayer @flobayer.bsky.social · 19/11/2025
Did you ever come across a phosphosite in your proteomics data for which nothing was known? - I bet so! We have developed a new strategy termed "potency coherence analysis" that leverages the drug potency dimension in decryptM to decode the kinases that shape the human phosphoproteome. Read more:
doi.org
Chemical proteomics decrypts the kinases that shape the dynamic human phosphoproteome
Mass-spectrometry-based phosphoproteomics enables the analysis of thousands of protein phosphorylation events across the human proteome. However, there is a lack of scalable, hypothesis-free, and stat...
2279
Florian P Bayer @flobayer.bsky.social · 18/11/2025
Very happy to see that dose-response curves are now super easy to access for everyone in proteomicsDB. Just a few clicks and you can see at which concentrations your favorite drug engages protein target(s), tinkers with signaling pathways, and inhibits cell growth. Read more: doi.org/10.1093/nar/...
doi.org
Mapping drug mechanisms with ProteomicsDB: unified omics and cell sensitivity data at scale
Abstract. Proteomic and phenotypic cell sensitivity datasets are increasingly important for understanding chemoproteomics and the underlying drug mechanism
161
Reposted by Florian P Bayer
Ludwig Lautenbacher @llautenbacher.bsky.social · 11/11/2025
Exited to share our latest work! Out now in @natcomms.nature.com Koina aims to transform how #proteomics uses machine learning. You no longer need to be a tech wizard to use ML and now can easily run #ML models. Integrated with FragPipe, Skyline and EncyclopeDIA! www.nature.com/articles/s41...
nature.com
Koina: Democratizing machine learning for proteomics research - Nature Communications
Koina is an open-source, online platform that simplifies access to machine learning models in proteomics, enabling easier integration into analysis tools and helping researchers adopt and reuse ML mod...
04116
Florian P Bayer @flobayer.bsky.social · 11/11/2025
A very clever approach to learn and predict MS2 spectra for modified peptides. By augmenting modification encodings and combining them with PROSIT, the new model has essentially generalized to ANY PTM - not just those in the training dataset. Super exciting !!
060
Florian P Bayer @flobayer.bsky.social · 31/07/2025
Very excited to see this story out in Science Signaling!! Especially the use of dose-dependent profiling at different time points could clearly separate immediate from late and consequential signaling changes in KRAS-driven (phospho)proteomes.
030
Reposted by Florian P Bayer
Nature Methods @natmethods.nature.com · 16/06/2025
Assessing error control is fundamental in mass spectrometry-based proteomics. @bo-wen.bsky.social @maccoss.bsky.social @urikeich.bsky.social et al introduce a theoretical foundation for entrapment along with a method for more accurate evaluation of FDR control. www.nature.com/articles/s41...
nature.com
Assessment of false discovery rate control in tandem mass spectrometry analysis using entrapment - Nature Methods
A theoretical foundation for entrapment methods is presented, along with a method that enables more accurate evaluation of false discovery rate (FDR) control in proteomics mass spectrometry analysis p...
0114
Florian P Bayer @flobayer.bsky.social · 04/06/2025
I am looking forward to discuss with with you: • (phospho)proteome-wide dose-response profiling • statistical analysis of 180 million curves with CurveCurator • mapping kinase-resolved activities changes due to all target engagements • (re-)evaluating the kinase substrate space in humans
040
Reposted by Florian P Bayer
Kusterlab @kusterlab.bsky.social · 22/05/2025
🚨Our new paper is online🚨 We use zero-distance⚡photo-crosslinking⚡to reveal direct protein-DNA interactions in living cells, enabling quantitative analysis of the DNA-interacting proteome on a timescale of minutes. #DNA #Chromatin #Proteomics www.cell.com/cell/fulltex...
cell.com
The human proteome with direct physical access to DNA
Zero-distance photo-crosslinking reveals direct protein-DNA interactions in living cells, enabling quantitative analysis of the DNA-interacting proteome on a timescale of minutes with single-amino-aci...
28639
Reposted by Florian P Bayer
Kusterlab @kusterlab.bsky.social · 22/04/2025
One algorithm to rule them all? CHIMERYS bridges the gap — DDA,DIA and PRM — together at last! With #CHIMERYS, we can now directly compare DDA and DIA data — 🍎 to 🍎 finally made possible. doi.org/10.1038/s41592-025-02663-w #KusterLab #WilhelmLab #MSAID #Proteomics
doi.org
Unifying the analysis of bottom-up proteomics data with CHIMERYS - Nature Methods
CHIMERYS is a spectrum-centric and data acquisition method-agnostic algorithm for the analysis of MS2 spectra. It is capable of deconvoluting any MS2 spectrum, regardless of whether it was acquired by...
0228
Reposted by Florian P Bayer
Kusterlab @kusterlab.bsky.social · 04/03/2025
🚀 Exciting news from our lab! Our latest paper has been featured on the cover of @molsystbiol.org - "Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response" by Höfer et al.! 🧬🎉 doi.org/10.1038/s44320-025-00085-6 (1/4)
doi.org
Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response | Molecular Systems Biology
imageimagePhosphoproteomics unveils the mode of action of clinical ATR inhibitors and explains their synergy with Gemcitabine in pancreatic cancer cells. Viability screening of 146 targeted drugs ide...
197
Florian P Bayer @flobayer.bsky.social · 23/02/2025
That is precisely why we are doing high-throughput, dose-dependent, (PTM)proteome-wide analyses to study MOAs of inhibitors, cell signaling, and cell adaptions. There is such a mess in the literature caused by either low throughput or single-dose perturbation experiments. That needs to be solved!
230
Florian P Bayer @flobayer.bsky.social · 27/01/2025
A very nice implementation of magnetic beads based competition pull-downs with DIA readout. This workflow is well suited for real throughput … CurveCurator is the perfect match for fast and reliable statistical analysis of these dose-response data sets.
020
Florian P Bayer @flobayer.bsky.social · 22/01/2025
Drug synergy is a fascinating phenomenon where 1+1=3. But what molecular mechanisms drive this effect? Our dose-resolved combination treatments with (phospho)proteome-wide readouts provide unprecedented quantitative detail of the DNA damage response. Read more: www.embopress.org/doi/full/10....
embopress.org
Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response | Molecular Systems Biology
imageimagePhosphoproteomics unveils the mode of action of clinical ATR inhibitors and explains their synergy with Gemcitabine in pancreatic cancer cells. Viability screening of 146 targeted drugs ide...
000
Florian P Bayer @flobayer.bsky.social · 20/01/2025
🎉🎉🎉
010
Florian P Bayer @flobayer.bsky.social · 10/01/2025
A very cool new tool to make sense out of proteome-wide perturbation data from a pathway perspective is now integrated in proteomicsDB. Especially decryptM data can be visualized well to see drug potencies for each p-site across a pathway of proteins. Check it out !!
020